SEARCH

Spread The News

Log in or Register to rate this News Story

 

More Industry Headlines

Will the EU medical device approval process get tougher? Expert analyst talks about a new potential challenge for the industry.

Prior authorization schemes don't save taxpayers money Congressional Budget Office scores health care programs, including imaging.

Q&A with a U.S. Army biomed To celebrate Healthcare Technology Management Week, here's a story of one biomed's unique journey.

Maryland governor signs breast density law Maryland joins the growing list of states to enact density notification laws.

FDA approves radiopharmaceutical to treat advanced prostate cancer Radioactive therapeutic agent can spare healthy tissue.

GE Healthcare unveils technology for imaging metal implants First-time software can create clear images despite metal.

Monarch Medical PET Services removes CEO Gary Moyers named interim CEO.

What technologies should we be using for mammography? A new study fills in the gaps in digital breast mammography.

Will the Angelina Jolie mastectomy test change cancer screening? The actress sheds awareness on new genetic screening tool for breast cancer.

New contrast agent could last longer than traditional dyes Researchers say they have found a cheaper, more effective dye.

Bracco gets FDA nod to expand Multihance indications

July 30, 2012
by Brendon Nafziger , DOTmed News Associate Editor
Bracco Diagnostics Inc. said Friday it received Food and Drug Administration approval to expand the indications of an MRI imaging agent used to detect brain tumors to now cover certain types of arterial disease.

Bracco said the drug, Multihance (gadobenate dimeglumine), now has been expanded for use in magnetic resonance angiographies to help diagnose stenosis in the renal and aorto-ilio-femoral arteries. The gadolinium-based contrast agent was originally approved by the FDA in 2004 for MRI scans of the central nervous system in children and adults.

Story Continues Below Advertisement

OiService - ISO 9001 & 13485 Certified - Call 888-673-5151

Oxford Instruments Service, is a leading ISO 9001 & 13485-certified organization,that specializes in providing quality after-market GE CT and MRI systems, serviceand parts - at prices you can afford.



The company said the approval came about after Bracco conducted two large, multi-center, prospective trials on the new indication.

As with other GBCAs, Multihance carries a black box warning label because of the risk of nephrogenic systemic fibrosis, believed to be an extremely rare side effect for patients with kidney problems who receive GBCA injections. However, in a statement, Dr. Alberto Spinazzi, senior vice president of regulatory affairs with Bracco, said Multihance carries a "strong record of safety" and has been administered more than 14 million times.

"Multihance has long been distinguished in the MRI of the CNS as a gadolinium-based contrast agent characterized by a strong increase in relaxivity in any medium containing serum proteins, contributing to increased contrast-to-noise ratio and lesion-to-brain ratio and improved visualization," he said.

Bracco Group is headquartered in Milan, Italy.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2013 DOTmed.com, Inc.
ALL RIGHTS RESERVED